This report contains market size and forecasts of Bioengineered Protein Drugs in global, including the following market information:
- Global Bioengineered Protein Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Bioengineered Protein Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Bioengineered Protein Drugs companies in 2021 (%)
The global Bioengineered Protein Drugs market was valued at 86200 million in 2021 and is projected to reach US$ 112310 million by 2028, at a CAGR of 3.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Bioengineered Protein Drugs include Dr.Reddy?s, Eli Lilly, Merck, Reliance Life Sciences, Panacea Biotech, Novartis, Fresenius, Sanofi and ProBioGen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Bioengineered Protein Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bioengineered Protein Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bioengineered Protein Drugs Market Segment Percentages, by Type, 2021 (%)
- Monoclonal Antibodies
- Therapeutic Proteins
- Vaccines
Global Bioengineered Protein Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bioengineered Protein Drugs Market Segment Percentages, by Application, 2021 (%)
- Cancer
- Diabetes
- Autoimmune Disorder
- Infectious Disease
- Neurodegenerative
- Others
Global Bioengineered Protein Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bioengineered Protein Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Bioengineered Protein Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Bioengineered Protein Drugs revenues share in global market, 2021 (%)
- Key companies Bioengineered Protein Drugs sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Bioengineered Protein Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Dr.Reddy?s
- Eli Lilly
- Merck
- Reliance Life Sciences
- Panacea Biotech
- Novartis
- Fresenius
- Sanofi
- ProBioGen
- GlaxoSmithKline
- Roche
- Amoytop Biotech
- Shanghai United Cell Biotechnology
- Hualan Bio
